SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (457)7/21/1999 12:39:00 PM
From: scaram(o)uche  Read Replies (1) of 579
 
No, when Lilly took the option, it became their game. Just depends on how strong the trend toward significance was and what the dose response data actually says about the potential.

Program is now well-funded by Lilly, 1553A results coming this quarter. If the 1553 results are negative or "grey", then SIBI turns into a plain old bargain (VGCC/pain, caspase, patents and licenses, BMY/Novartis/Lilly), instead of a potential skyrocket with short fuse.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2024 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News